Urogen Pharma Ltd (NASDAQ:URGN) saw a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,033,334 shares, a growth of 34.1% from the January 15th total of 770,675 shares. Based on an average daily volume of 533,914 shares, the short-interest ratio is presently 1.9 days. Approximately 6.5% of the company’s shares are short sold.
Shares of URGN stock opened at $40.51 on Thursday. The stock has a market capitalization of $561.45 million, a price-to-earnings ratio of -18.93 and a beta of 1.60. Urogen Pharma has a one year low of $36.95 and a one year high of $69.57.
Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, November 15th. The company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The company had revenue of $0.28 million during the quarter. Urogen Pharma had a negative return on equity of 61.06% and a negative net margin of 4,296.08%. On average, sell-side analysts anticipate that Urogen Pharma will post -4.56 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of URGN. BlackRock Inc. bought a new position in Urogen Pharma in the 2nd quarter worth about $4,468,000. California Public Employees Retirement System bought a new position in Urogen Pharma in the 2nd quarter worth about $840,000. Jane Street Group LLC bought a new position in Urogen Pharma in the 2nd quarter worth about $227,000. Northern Trust Corp bought a new position in Urogen Pharma in the 2nd quarter worth about $677,000. Finally, Rothschild Investment Corp IL bought a new position in Urogen Pharma in the 3rd quarter worth about $201,000. Institutional investors and hedge funds own 72.22% of the company’s stock.
Several brokerages recently commented on URGN. Jefferies Financial Group began coverage on shares of Urogen Pharma in a report on Thursday, November 8th. They set a “buy” rating and a $77.00 price target on the stock. Oppenheimer set a $75.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a report on Tuesday, November 13th. Zacks Investment Research downgraded shares of Urogen Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. Finally, HC Wainwright began coverage on shares of Urogen Pharma in a report on Tuesday, January 29th. They set a “buy” rating and a $82.00 price target on the stock. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $73.80.
ILLEGAL ACTIVITY NOTICE: “Short Interest in Urogen Pharma Ltd (URGN) Grows By 34.1%” was published by Enterprise Leader and is owned by of Enterprise Leader. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://theenterpriseleader.com/2019/02/14/short-interest-in-urogen-pharma-ltd-urgn-grows-by-34-1.html.
About Urogen Pharma
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
See Also: What is a Derivative?
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.